Burning Rock Biotech Limited — Cyborg Score 6/10

Strategic Profile

The company differentiates through proprietary NGS assays including OncoScreen, OncoCompass, and CanCatch platforms that enable both therapy selection and early cancer detection. Strategic partnerships with major pharmaceutical companies including AstraZeneca, Bayer, and Johnson & Johnson strengthen competitive positioning in companion diagnostics and clinical trial biomarker detection services.

Cyborg Score Rationale

Burning Rock holds market leadership in China's NGS-based cancer testing market with strong regulatory recognition, including NMPA breakthrough designation for early cancer detection. However, revenue growth remains modest (0.8% YoY in Q3 2024), reflecting market maturation and business model transition challenges from central lab to in-hospital testing.

Top Insights

• Market leader in NGS-based cancer therapy selection in China, commanding largest patient test volume
• Expanding in-hospital diagnostic business (17% YoY growth in Q3 2024) while managing central lab transition
• Strong pharma partnerships driving companion diagnostics approvals and clinical trial collaboration opportunities
• Clinical-stage cancer early detection (OverC multi-cancer screening) advancing through clinical validation with regulatory breakthrough designation

Named Competitors

• Guardant360 — Liquid biopsy ctDNA testing for cancer detection and monitoring
• myChoice Tumor Testing — In-licensed HGSOC diagnostic with Burning Rock partnership in China
• FoundationOne — Tissue-based comprehensive genomic profiling for therapy selection

Recent Developments

• (October 2024) Companion diagnostic for sunvozertinib approved by NMPA - first co-developed NGS-based CDx for lung cancer post-NMPA guideline
• (September 2024) Active participation in precision oncology conferences showcasing advanced assays and research
• (2025) Continued expansion of pharma partnerships and clinical trial biomarker detection services
• (Q3 2024) Revenue stabilization at RMB128.6M with strategic shift toward higher-margin in-hospital testing

Open the full interactive Burning Rock Biotech Limited report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.